ADAP:NSD-Adaptimmune Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.47

Change

-0.32 (-3.27)%

Market Cap

USD 1.42B

Volume

0.63M

Average Target Price

USD 7.00 (-26.08%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+0.21 (+0.07%)

USD75.50B 48.39 36.24
REGN Regeneron Pharmaceuticals, Inc

+4.80 (+0.77%)

USD62.07B 30.02 20.75
SGEN Seattle Genetics, Inc

+1.42 (+0.84%)

USD29.51B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.27 (+1.13%)

USD25.08B 10.60 9.11
INCY Incyte Corporation

+1.32 (+1.24%)

USD22.68B 47.64 35.20
MRNA Moderna, Inc

+0.58 (+0.99%)

USD21.96B N/A N/A
BMRN BioMarin Pharmaceutical Inc

+0.93 (+0.73%)

USD21.81B 193.21 115.90
GMAB Genmab A/S

+0.82 (+2.45%)

USD21.51B 59.03 6.26
ALNY Alnylam Pharmaceuticals, Inc

+2.56 (+1.71%)

USD17.42B N/A N/A
BGNE BeiGene, Ltd

+0.86 (+0.44%)

USD15.19B N/A N/A

ETFs Containing ADAP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 689.17% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 689.17% 98% A+ 98% A+
Trailing 12 Months  
Capital Gain 155.95% 89% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 155.95% 89% B+ 94% A
Trailing 5 Years  
Capital Gain -45.73% 50% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.73% 49% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain -3.69% 43% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.69% 42% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 74.48% 27% F 13% F
Risk Adjusted Return -4.96% 48% F 27% F
Market Capitalization 1.42B 79% C+ 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.96 27% F 16% F
Price / Cash Flow Ratio -12.64 70% C- 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -67.99% 51% F 19% F
Return on Invested Capital -75.58% 39% F 13% F
Return on Assets -30.54% 47% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.49 80% B- 81% B-
Short Percent N/A N/A N/A N/A N/A
Beta 2.42 13% F 7% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector